Biovica International Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
37
- Stock Symbol
-
BIOVIC B
- Share Price
-
$0.25
- (As of Thursday Closing)
Biovica International General Information
Description
Biovica International AB is a biotech company. It develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments. Through collaboration with world- leading cancer institutes and pharmaceutical companies, it promotes the trend in healthcare for personalized treatment, with a primary focus on patient survival and benefits to society. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.
Contact Information
- Dag Hammarskjölds väg 54B
- Uppsala Science Park
- 752 37 Uppsala
- Sweden
Biovica International Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.25 | $0.24 | $0.21 - $0.97 | $11.3M | 45.7M | 107K | -$0.26 |
Biovica International Financials Summary
|
In Thousands, USD |
TTM 31-Oct-2023 | FY 2023 30-Apr-2023 | FY 2022 30-Apr-2022 | FY 2021 30-Apr-2021 |
|---|---|---|---|---|
| EV | 3,941 | 19,281 | 80,351 | 119,960 |
| Revenue | 582 | 323 | 230 | 237 |
| EBITDA | (10,874) | (9,796) | (6,010) | (3,878) |
| Net Income | (11,671) | (10,535) | (6,734) | (4,498) |
| Total Assets | 9,345 | 16,780 | 15,337 | 23,018 |
| Total Debt | 840 | 1,018 | 1,340 | 289 |
Biovica International Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biovica International Comparisons
Industry
Financing
Details
000000
00000
Biovica International Competitors (4)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adaptive Biotechnologies | Formerly VC-backed | Seattle, WA | 000 | 00000 | 00000000 | 00000 |
| 00000 00000000 | Formerly VC-backed | Madison, WI | 0000 | 00.000 | 00000000 | 00.000 |
| 0000000000 | Corporate Backed or Acquired | Huntingdon Valley, PA | 000000&0 | |||
| 000 00000000 | Formerly VC-backed | Shenzhen, China | 0000 | 00000 | 000000000 | 00000 |
Biovica International Patents
Biovica International Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-9429518-B2 | Kit and method | Active | 14-May-2010 | 000000000 | 00 |
| US-20130071846-A1 | Kit and method | Active | 14-May-2010 | 000000000 | 0 |
| US-20170029867-A1 | Kit and method | Active | 14-May-2010 | 000000000 | |
| US-10190149-B2 | Kit and method for measuring the activity of deoxynucleoside kinase | Active | 14-May-2010 | 000000000 | 00 |
| JP-6409233-B2 | Kits and methods | Active | 14-May-2010 | C12Q1/485 |
Biovica International Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Anders Rylander | Chief Executive Officer & Board Member | ||
| Anders Moren | Group Chief Executive Officer |
Biovica International Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Anders Rylander | Biovica International | Chief Executive Officer & Board Member | 000 0000 |
| Annika Berg | Self | Board Member | 000 0000 |
| Henrik Osvald | Self | Board Member | 000 0000 |
| Jarl Jungnelius Ph.D | Self | Director of the Board and Senior Oncology Advisor | 000 0000 |
| Jesper Söderqvist Ph.D | Self | Board Member | 000 0000 |
Biovica International Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Biovica International Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Biovica International ESG
Risk Overview
Risk Rating
Updated November, 22, 2022
26.34 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,708
Rank
Percentile
Pharmaceuticals
Industry
00 of 884
Rank
Percentile
Biotechnology
Subindustry
00 of 399
Rank
Percentile
